Recombinant osteoprotegerin - Amgen

Drug Profile

Recombinant osteoprotegerin - Amgen

Alternative Names: AMGN-0007; OCIF - Amgen; OPG - Amgen; Osteoclastogenesis Inhibiting Factor - Amgen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hyperparathyroidism
  • Discontinued Bone disorders; Cancer pain; Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperparathyroidism in USA
  • 15 Sep 2009 Preclinical trials in Hyperparathyroidism in USA (unspecified route)
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Hyperparathyroidism presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top